# US 2014/0194428 A1 · Combination treatments for bipolar disorders > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0194428 A1 - Document ID: US20140194428A1 - Status: Published application - Kind: A1 - Application number: 13/573,640 - Filed: 2012-09-28 - Published: 2014-07-10 - Earliest claimed: 2012-09-28 - Assignees: Elan Pharmaceuticals, Inc. - Inventors: Susan Abushakra; Gerald Crans; Ramon Hernandez; Jesse Cedarbaum - Web page: https://patentgrep.com/patent/US20140194428A1 ## CPC - A61K 31/53: having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine (melarsoprol A61K31/555 {; with four nitrogen atoms A61K31/495}) - A61K 31/20: having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids - A61K 31/7004: Monosaccharides having only carbon, hydrogen and oxygen atoms - A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D) ## Abstract The invention relates generally to novel compositions and methods comprising a scyllo-inositol compound and one or both of valproic acid compound and lamotrigine. The compositions and methods provide beneficial effects in the treatment of bipolar disorders. ## Claims ### Claim 1 A method of delaying the occurrence of a mood episode in a subject having bipolar disorder comprising administering to said subject effective amounts of scyllo-inositol and one or both of valproic acid and lamotrigine. ### Claim 2 A method of reducing the level of myo-inositol in the brain of a subject comprising administering to the subject effective amounts of scyllo-inositol and one or both of valproic acid and lamotrigine. ### Claim 3 A method for treating a bipolar disorder comprising administering to the subject a combination of an effective amount of scyllo-inositol and an effective amount of one or both of a valproic acid compound and lamotrigine. ### Claim 4 (depends on 3) The method as claimed in claim 3 wherein the bipolar disorder is bipolar I disorder. ### Claim 5 (depends on 1, 2, 3) The method as claimed in any one of claims 1 to 3 wherein the effective amounts of scyllo-inositol and one or both of valproic acid and lamotrigine are combined and administered to the subject in a single formulation. ### Claim 6 (depends on 1, 2, 3) The method as claimed in any one of claims 1 to 3 wherein the effective amounts of the scyllo-inositol compound and one or both of a valproic acid compound and lamotrigine are administered to the subject sequentially. ### Claim 7 (depends on 1, 2, 3) The method as claimed in any one of claims 1 to 3, wherein the subject is administered an effective amount of scyllo-inositol and an effective amount of valproic acid and not lamotragine. ### Claim 8 (depends on 7) The method as claimed in claim 7, wherein valproic acid is administered to the subject prior to scyllo-inositol. ### Claim 9 (depends on 8) The method as claimed in claim 8, wherein the concentration of valproic acid in the subject's plasma is about 1 to 500 μg/mL. ### Claim 10 (depends on 8) The method as claimed in claim 8, wherein the concentration of valproic acid in the subject's plasma is about 50 to 125 μg/mL. ### Claim 11 (depends on 8) The method as claimed in claim 8, wherein the concentration of valproic acid in the subject's plasma is between 50 and 125 μg/mL. ### Claim 12 (depends on 6) The method as claimed in claim 6, wherein the combination administered to the subject is an effective amount of scyllo-inositol and an effective amount of lamotrigine and not valproic acid. ### Claim 13 (depends on 12) The method as claimed in claim 12, wherein lamotrigine is administered to the subject prior to scyllo-inositol. ### Claim 14 (depends on 13) The method as claimed in claim 13, wherein the concentration of lamotrigine in the subject's plasma is about 1 to 500 μg/mL. ### Claim 15 (depends on 13) The method as claimed in claim 13, wherein the concentration of lamotrigine in the subject's plasma is about 10 to 50 μg/mL. ### Claim 16 (depends on 13) The method as claimed in claim 13, wherein the concentration of lamotrigine in the subject's plasma is between 10 and 50 μg/mL. ### Claim 17 (depends on 1, 2, 3) The method as claimed in any one of claims 1 to 3, wherein the amount of scyllo-inositol administered to the subject is from 1 to 5,000 mg/day. ### Claim 18 (depends on 17) The method as claimed in claim 17 wherein the amount of scyllo-inositol administered to the subject is from 100 to 2,000 mg/day. ### Claim 19 (depends on 17) The method as claimed in claim 17 wherein the amount of scyllo-inositol administered to the subject is 1,000 mg/day. ### Claim 20 (depends on 17) The method as claimed in claim 17 wherein the amount of scyllo-inositol administered to the subject is 500 mg BID. ### Claim 21 (depends on 12) The method as claimed in claim 12 wherein the amount of scyllo-inositol administered is 500 mg BID and the concentration of valproic acid in the subject's plasma is is between 50 and 125 μg/mL. ### Claim 22 (depends on 17) The method as claimed in claim 17 wherein the amount of scyllo-inositol administered is 500 mg BID and the concentration of lamotrigine in the subject's plasma is between 10 and 50 μg/mL. ### Claim 23 (depends on 1) The method as claimed in claim 1 wherein the effective amounts of the scyllo-inositol compound and one or both of a valproic acid compound and lamotrigine are synergistically effective amounts. ### Claim 24 A pharmaceutical composition for treating a bipolar disorder comprising a scyllo-inositol compound and one or both of a valproic acid compound and lamotrigine. ### Claim 25 (depends on 24) The pharmaceutical composition according to claim 24 comprising about 100 to about 1500 mg of the scyllo-inositol compound. ### Claim 26 Use of a scyllo-inositol compound and one or both of a valproic acid compound and lamotrigine for the treatment of a bipolar disorder. ### Claim 27 A kit comprising a scyllo-inositol compound and one or both of a valproic acid compound and lamotrigine, a container, and instructions for use in the treatment of a bipolar disorder in a subject.